Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...